Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease. / Jørgensen, Morten B.; Idorn, Thomas; Rydahl, Casper; Hansen, Henrik P.; Bressendorff, Iain; Brandi, Lisbet; Wewer Albrechtsen, Nicolai J.; Van Hall, Gerrit; Hartmann, Bolette; Holst, Jens J.; Knop, Filip K.; Hornum, Mads; Feldt-Rasmussen, Bo.

I: Journal of Clinical Endocrinology and Metabolism, Bind 105, Nr. 3, 01.2020, s. e564-e574.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Jørgensen, MB, Idorn, T, Rydahl, C, Hansen, HP, Bressendorff, I, Brandi, L, Wewer Albrechtsen, NJ, Van Hall, G, Hartmann, B, Holst, JJ, Knop, FK, Hornum, M & Feldt-Rasmussen, B 2020, 'Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease', Journal of Clinical Endocrinology and Metabolism, bind 105, nr. 3, s. e564-e574. https://doi.org/10.1210/clinem/dgz048

APA

Jørgensen, M. B., Idorn, T., Rydahl, C., Hansen, H. P., Bressendorff, I., Brandi, L., Wewer Albrechtsen, N. J., Van Hall, G., Hartmann, B., Holst, J. J., Knop, F. K., Hornum, M., & Feldt-Rasmussen, B. (2020). Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease. Journal of Clinical Endocrinology and Metabolism, 105(3), e564-e574. https://doi.org/10.1210/clinem/dgz048

Vancouver

Jørgensen MB, Idorn T, Rydahl C, Hansen HP, Bressendorff I, Brandi L o.a. Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease. Journal of Clinical Endocrinology and Metabolism. 2020 jan.;105(3):e564-e574. https://doi.org/10.1210/clinem/dgz048

Author

Jørgensen, Morten B. ; Idorn, Thomas ; Rydahl, Casper ; Hansen, Henrik P. ; Bressendorff, Iain ; Brandi, Lisbet ; Wewer Albrechtsen, Nicolai J. ; Van Hall, Gerrit ; Hartmann, Bolette ; Holst, Jens J. ; Knop, Filip K. ; Hornum, Mads ; Feldt-Rasmussen, Bo. / Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease. I: Journal of Clinical Endocrinology and Metabolism. 2020 ; Bind 105, Nr. 3. s. e564-e574.

Bibtex

@article{9bb2b42772d34330b2e3c1138ae8489d,
title = "Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease",
abstract = "Context: The insulin-stimulating and glucagon-regulating effects of the 2 incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), contribute to maintain normal glucose homeostasis. Impaired glucose tolerance occurs with high prevalence among patients with end-stage renal disease (ESRD). Objective: To evaluate the effect of the incretin hormones on endocrine pancreatic function in patients with ESRD. Design and Setting: Twelve ESRD patients on chronic hemodialysis and 12 matched healthy controls, all with normal oral glucose tolerance test, were included. On 3 separate days, a 2-hour euglycemic clamp followed by a 2-hour hyperglycemic clamp (3 mM above fasting level) was performed with concomitant infusion of GLP-1 (1 pmol/kg/min), GIP (2 pmol/kg/min), or saline administered in a randomized, double-blinded fashion. A 30% lower infusion rate was used in the ESRD group to obtain comparable incretin hormone plasma levels. Results: During clamps, comparable plasma glucose and intact incretin hormone concentrations were achieved. The effect of GLP-1 to increase insulin concentrations relative to placebo levels tended to be lower during euglycemia in ESRD and was significantly reduced during hyperglycemia (50 [8-72]%, P = 0.03). Similarly, the effect of GIP relative to placebo levels tended to be lower during euglycemia in ESRD and was significantly reduced during hyperglycemia (34 [13-50]%, P = 0.005). Glucagon was suppressed in both groups, with controls reaching lower concentrations than ESRD patients. Conclusions: The effect of incretin hormones to increase insulin release is reduced in ESRD, which, together with elevated glucagon levels, could contribute to the high prevalence of impaired glucose tolerance among ESRD patients.",
author = "J{\o}rgensen, {Morten B.} and Thomas Idorn and Casper Rydahl and Hansen, {Henrik P.} and Iain Bressendorff and Lisbet Brandi and {Wewer Albrechtsen}, {Nicolai J.} and {Van Hall}, Gerrit and Bolette Hartmann and Holst, {Jens J.} and Knop, {Filip K.} and Mads Hornum and Bo Feldt-Rasmussen",
year = "2020",
month = jan,
doi = "10.1210/clinem/dgz048",
language = "English",
volume = "105",
pages = "e564--e574",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Oxford University Press",
number = "3",

}

RIS

TY - JOUR

T1 - Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease

AU - Jørgensen, Morten B.

AU - Idorn, Thomas

AU - Rydahl, Casper

AU - Hansen, Henrik P.

AU - Bressendorff, Iain

AU - Brandi, Lisbet

AU - Wewer Albrechtsen, Nicolai J.

AU - Van Hall, Gerrit

AU - Hartmann, Bolette

AU - Holst, Jens J.

AU - Knop, Filip K.

AU - Hornum, Mads

AU - Feldt-Rasmussen, Bo

PY - 2020/1

Y1 - 2020/1

N2 - Context: The insulin-stimulating and glucagon-regulating effects of the 2 incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), contribute to maintain normal glucose homeostasis. Impaired glucose tolerance occurs with high prevalence among patients with end-stage renal disease (ESRD). Objective: To evaluate the effect of the incretin hormones on endocrine pancreatic function in patients with ESRD. Design and Setting: Twelve ESRD patients on chronic hemodialysis and 12 matched healthy controls, all with normal oral glucose tolerance test, were included. On 3 separate days, a 2-hour euglycemic clamp followed by a 2-hour hyperglycemic clamp (3 mM above fasting level) was performed with concomitant infusion of GLP-1 (1 pmol/kg/min), GIP (2 pmol/kg/min), or saline administered in a randomized, double-blinded fashion. A 30% lower infusion rate was used in the ESRD group to obtain comparable incretin hormone plasma levels. Results: During clamps, comparable plasma glucose and intact incretin hormone concentrations were achieved. The effect of GLP-1 to increase insulin concentrations relative to placebo levels tended to be lower during euglycemia in ESRD and was significantly reduced during hyperglycemia (50 [8-72]%, P = 0.03). Similarly, the effect of GIP relative to placebo levels tended to be lower during euglycemia in ESRD and was significantly reduced during hyperglycemia (34 [13-50]%, P = 0.005). Glucagon was suppressed in both groups, with controls reaching lower concentrations than ESRD patients. Conclusions: The effect of incretin hormones to increase insulin release is reduced in ESRD, which, together with elevated glucagon levels, could contribute to the high prevalence of impaired glucose tolerance among ESRD patients.

AB - Context: The insulin-stimulating and glucagon-regulating effects of the 2 incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), contribute to maintain normal glucose homeostasis. Impaired glucose tolerance occurs with high prevalence among patients with end-stage renal disease (ESRD). Objective: To evaluate the effect of the incretin hormones on endocrine pancreatic function in patients with ESRD. Design and Setting: Twelve ESRD patients on chronic hemodialysis and 12 matched healthy controls, all with normal oral glucose tolerance test, were included. On 3 separate days, a 2-hour euglycemic clamp followed by a 2-hour hyperglycemic clamp (3 mM above fasting level) was performed with concomitant infusion of GLP-1 (1 pmol/kg/min), GIP (2 pmol/kg/min), or saline administered in a randomized, double-blinded fashion. A 30% lower infusion rate was used in the ESRD group to obtain comparable incretin hormone plasma levels. Results: During clamps, comparable plasma glucose and intact incretin hormone concentrations were achieved. The effect of GLP-1 to increase insulin concentrations relative to placebo levels tended to be lower during euglycemia in ESRD and was significantly reduced during hyperglycemia (50 [8-72]%, P = 0.03). Similarly, the effect of GIP relative to placebo levels tended to be lower during euglycemia in ESRD and was significantly reduced during hyperglycemia (34 [13-50]%, P = 0.005). Glucagon was suppressed in both groups, with controls reaching lower concentrations than ESRD patients. Conclusions: The effect of incretin hormones to increase insulin release is reduced in ESRD, which, together with elevated glucagon levels, could contribute to the high prevalence of impaired glucose tolerance among ESRD patients.

U2 - 10.1210/clinem/dgz048

DO - 10.1210/clinem/dgz048

M3 - Journal article

C2 - 31608934

AN - SCOPUS:85077666349

VL - 105

SP - e564-e574

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 3

ER -

ID: 243525394